How to buy Catalyst Biosciences stock | $5.77

Catalyst Biosciences, Inc is a biotechnology business based in the US. Catalyst Biosciences shares (CBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Biosciences employs 34 staff and has a trailing 12-month revenue of around USD$18.9 million.

How to buy shares in Catalyst Biosciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Catalyst Biosciences. Find the stock by name or ticker symbol: CBIO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Catalyst Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$5.77, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Catalyst Biosciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Catalyst Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Catalyst Biosciences share price

Use our graph to track the performance of CBIO stocks over time.

Catalyst Biosciences shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$5.77
52-week range	USD$3.43 - USD$8.66
50-day moving average	USD$6.1321
200-day moving average	USD$5.6208
Wall St. target price	USD$20.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.961

Buy Catalyst Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Catalyst Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Catalyst Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalyst Biosciences price performance over time

Historical closes compared with the close of $5.77 from 2020-12-09

1 week (2021-01-07)	-7.09%
1 month (2020-12-17)	-16.50%
3 months (2020-10-16)	-9.98%
6 months (2020-07-16)	0.17%

1 year (2020-01-16)	-21.17%
2 years (2019-01-16)	-29.81%
3 years (2018-01-16)	14.18
5 years (2016-01-15)	157.59%

Is Catalyst Biosciences under- or over-valued?

Valuing Catalyst Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Biosciences's PEG ratio

Catalyst Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalyst Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Catalyst Biosciences financials

Revenue TTM	USD$18.9 million
Gross profit TTM	USD$-43,859,000
Return on assets TTM	-31.75%
Return on equity TTM	-58.11%
Profit margin	-269.3%
Book value	$4.259
Market capitalisation	USD$143 million

TTM: trailing 12 months

Shorting Catalyst Biosciences shares

There are currently 912,042 Catalyst Biosciences shares held short by investors – that's known as Catalyst Biosciences's "short interest". This figure is 6.6% down from 976,001 last month.

There are a few different ways that this level of interest in shorting Catalyst Biosciences shares can be evaluated.

Catalyst Biosciences's "short interest ratio" (SIR)

Catalyst Biosciences's "short interest ratio" (SIR) is the quantity of Catalyst Biosciences shares currently shorted divided by the average quantity of Catalyst Biosciences shares traded daily (recently around 323419.14893617). Catalyst Biosciences's SIR currently stands at 2.82. In other words for every 100,000 Catalyst Biosciences shares traded daily on the market, roughly 2820 shares are currently held short.

However Catalyst Biosciences's short interest can also be evaluated against the total number of Catalyst Biosciences shares, or, against the total number of tradable Catalyst Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalyst Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Catalyst Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0327% of the tradable shares (for every 100,000 tradable Catalyst Biosciences shares, roughly 33 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalyst Biosciences.

Find out more about how you can short Catalyst Biosciences stock.

Catalyst Biosciences share dividends

We're not expecting Catalyst Biosciences to pay a dividend over the next 12 months.

Have Catalyst Biosciences's shares ever split?

Catalyst Biosciences's shares were split on a 1:15 basis on 13 February 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catalyst Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Catalyst Biosciences shares which in turn could have impacted Catalyst Biosciences's share price.

Catalyst Biosciences share price volatility

Over the last 12 months, Catalyst Biosciences's shares have ranged in value from as little as $3.43 up to $8.66. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Biosciences's is 2.0577. This would suggest that Catalyst Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Catalyst Biosciences overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Frequently asked questions

• What percentage of Catalyst Biosciences is owned by insiders or institutions?

  Currently 4.551% of Catalyst Biosciences shares are held by insiders and 65.164% by institutions.

• How many people work for Catalyst Biosciences?

  Latest data suggests 34 work at Catalyst Biosciences.

• When does the fiscal year end for Catalyst Biosciences?

  Catalyst Biosciences's fiscal year ends in December.

• Where is Catalyst Biosciences based?

  Catalyst Biosciences's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080

• What is Catalyst Biosciences's ISIN number?

  Catalyst Biosciences's international securities identification number is: US14888D2080

• What is Catalyst Biosciences's CUSIP number?

  Catalyst Biosciences's Committee on Uniform Securities Identification Procedures number is: 14888D109